Reduced serum LEFTY2 and disease-dependent biomarker associations in Alzheimer's disease: an exploratory study.
7 affiliations
- 1Bioinnovation Center, Hualien Tzu Chi Hospital, Hualien, Taiwan.
- 2Center for Dementia Care, St. Mary's Hospital, Taitung, Taiwan.
- 3Department of Biochemistry and Molecular Medicine, National Dong Hwa University, Hualien, Taiwan.
- 4Department of Neurology, Hualien Tzu Chi Hospital, Hualien, Taiwan.
- 5Department of Pathology, Hualien Tzu Chi Hospital, Hualien, Taiwan.
- 6Ph.D. Program of Interdisciplinary Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- 7Department of Neurosurgery, Hualien Tzu Chi Hospital, Hualien, Taiwan.
Abstract
Reliable blood-based biomarkers are increasingly needed for the detection and monitoring of Alzheimer's disease (AD). Left-right determination factor 2 (LEFTY2) is a secreted protein of the transforming growth factor-β (TGF-β) superfamily. Evidence from AD-related neuronal models suggests that LEFTY2 promotes neuronal survival, attenuates amyloid- and tau-related pathology, and suppresses inflammatory responses, highlighting its potential relevance to AD. However, its clinical significance and relationship with AD-related blood biomarkers remain unclear. In this study, we investigated the association between serum LEFTY2 and and biomarkers associated with amyloid pathology, tau pathology, neuroinflammation, and neurodegeneration in patients with AD and age-matched cognitively normal (CN) controls. Biomarker levels were quantified using enzyme-linked immunosorbent assays. Serum LEFTY2 levels were significantly lower in AD patients than in cognitively normal controls, whereas Amyloid-beta 1-40 (Aβ1-40), phosphorylated tau (pTau) 181 and Neurofilament light chain (NF-L) levels were significantly elevated. Correlation analyses revealed a positive association between LEFTY2 and Aβ1-42 in AD patients, while correlations with biomarkers of tau pathology, inflammation, and neurodegeneration were less consistent. In cognitively normal controls, LEFTY2 was negatively correlated with total tau and positively correlated with TGF-β1. Collectively, these findings indicate that LEFTY2 exhibits distinct associations with AD-related biomarkers in a disease-dependent manner. These exploratory findings provide new insights into the relationships among circulating AD biomarkers and support further investigation of LEFTY2 as a novel candidate blood-based marker in larger prospective cohorts.
Related
- Exploratory Analysis of APOE ε4-Stratified Associations Between Plasma Alzheimer's Biomarkers and Retinal Imaging Metrics in Cognitively Normal Adults.
- Biomarker−dependent detection of contrast−associated acute kidney injury after intra−arterial contrast procedures: an exploratory randomized trial
- Cross-sectional associations of Kidney deficiency, Phlegm-stasis, and Heat-toxin syndrome patterns with disease severity in Alzheimer’s disease: an exploratory study
- Reduced serum Dickkopf-1 levels as a potential supportive biomarker for the development and severity of retinopathy of prematurity: a prospective observational clinical study
- Single-cell, spatial, and machine learning analyses identify ANKIB1 as an oligodendrocyte-anchored palmitoylation-associated candidate biomarker of Alzheimer’s disease
BibTeX
@article{wuli2026reduced,
title = {{Reduced serum LEFTY2 and disease-dependent biomarker associations in Alzheimer's disease: an exploratory study.}},
author = {Wei Wuli and Raymond Y Lo and Horng-Jyh Harn and Tzyy-Wen Chiou and Yue-Xuan Xu and Yuncin Luo and Ivan Wijaya and Shinn-Zong Lin},
journal = {Frontiers in aging neuroscience},
year = {2026},
month = oct,
doi = {10.3389/fnagi.2026.1955495},
url = {https://europepmc.org/article/MED/42903321},
note = {CC BY},
}
RIS
TY - JOUR
TI - Reduced serum LEFTY2 and disease-dependent biomarker associations in Alzheimer's disease: an exploratory study.
AU - Wei Wuli
AU - Raymond Y Lo
AU - Horng-Jyh Harn
AU - Tzyy-Wen Chiou
AU - Yue-Xuan Xu
AU - Yuncin Luo
AU - Ivan Wijaya
AU - Shinn-Zong Lin
PY - 2026
DA - 2026/10/06
JO - Frontiers in aging neuroscience
DO - 10.3389/fnagi.2026.1955495
UR - https://europepmc.org/article/MED/42903321
AB - Reliable blood-based biomarkers are increasingly needed for the detection and monitoring of Alzheimer's disease (AD). Left-right determination factor 2 (LEFTY2) is a secreted protein of the transforming growth factor-β (TGF-β) superfamily. Evidence from AD-related neuronal models suggests that LEFTY2 promotes neuronal survival, attenuates amyloid- and tau-related pathology, and suppresses inflammatory responses, highlighting its potential relevance to AD. However, its clinical significance and relationship with AD-related blood biomarkers remain unclear. In this study, we investigated the association between serum LEFTY2 and and biomarkers associated with amyloid pathology, tau pathology, neuroinflammation, and neurodegeneration in patients with AD and age-matched cognitively normal (CN) controls. Biomarker levels were quantified using enzyme-linked immunosorbent assays. Serum LEFTY2 levels were significantly lower in AD patients than in cognitively normal controls, whereas Amyloid-beta 1-40 (Aβ1-40), phosphorylated tau (pTau) 181 and Neurofilament light chain (NF-L) levels were significantly elevated. Correlation analyses revealed a positive association between LEFTY2 and Aβ1-42 in AD patients, while correlations with biomarkers of tau pathology, inflammation, and neurodegeneration were less consistent. In cognitively normal controls, LEFTY2 was negatively correlated with total tau and positively correlated with TGF-β1. Collectively, these findings indicate that LEFTY2 exhibits distinct associations with AD-related biomarkers in a disease-dependent manner. These exploratory findings provide new insights into the relationships among circulating AD biomarkers and support further investigation of LEFTY2 as a novel candidate blood-based marker in larger prospective cohorts.
SN - 1663-4365
ER -